Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

R. Gold, EW. Radue, G. Giovannoni, K. Selmaj, E. Havrdova, D. Stefoski, T. Sprenger, X. Montalban, S. Cohan, K. Umans, SJ. Greenberg, G. Ozen, J. Elkins,

. 2016 ; 16 (-) : 117. [pub] 20160726

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, srovnávací studie, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000239

BACKGROUND: Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy of daclizumab in patients with relapsing-remitting multiple sclerosis (RRMS). We report the long-term safety and efficacy of daclizumab 150 mg subcutaneous every 4 weeks in patients with RRMS in the SELECTED open-label extension study. METHODS: An interim intent-to-treat analysis of all enrolled patients was performed in January 2014 for this ongoing study. RESULTS: The SELECTED study enrolled 90% of patients who completed SELECTION. In the safety and efficacy analysis (N = 410), median treatment time in SELECTED was 25 months (range, <1-45). Adverse events (AEs) were reported in 76% of patients, serious AEs (SAEs) excluding MS relapse in 16%, and treatment discontinuation due to AEs including multiple sclerosis (MS) relapse in 12%. AEs were primarily of mild to moderate severity, and common AEs (≥10%), excluding MS relapse, were nasopharyngitis (12%) and upper respiratory tract infection (12%). Most commonly reported SAEs (in ≥3 patients), excluding MS relapses, were increased serum hepatic enzymes, pneumonia, ulcerative colitis, and urinary tract infection (<1% each). Incidences of AE groups of interest include cutaneous events (28%), cutaneous SAEs (2%), gastrointestinal SAEs (2%), hepatic SAEs, (1%) and malignancies (1%). The incidence of AEs, SAEs, and treatment-related study discontinuations did not increase over time and no deaths were reported. The adjusted annualized relapse rate (95% confidence interval (CI)) analyzed at 6-month intervals was 0.15 (0.10-0.22) for weeks 97-120 and 0.15 (0.10-0.21) for weeks 121-144. In year 3, the adjusted mean (95% CI) number of new/newly enlarging T2 hyperintense lesions was 1.26 (0.93-1.72) and the mean (median) annualized change in brain volume was -0.32% (-0.34%). CONCLUSIONS: The AE incidence did not increase with extension of therapy into year 3 in SELECTED; the safety profile was similar to that previously observed. The clinical efficacy of daclizumab was sustained over the 3 years comprising the SELECT TRILOGY, although potential selection bias cannot be excluded. TRIAL REGISTRATION: Clinicaltrials.gov NCT01051349; first registered January 15, 2010.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000239
003      
CZ-PrNML
005      
20170112123525.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12883-016-0635-y $2 doi
024    7_
$a 10.1186/s12883-016-0635-y $2 doi
035    __
$a (PubMed)27461166
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gold, Ralf $u Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany. ralf.gold@rub.de.
245    10
$a Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study / $c R. Gold, EW. Radue, G. Giovannoni, K. Selmaj, E. Havrdova, D. Stefoski, T. Sprenger, X. Montalban, S. Cohan, K. Umans, SJ. Greenberg, G. Ozen, J. Elkins,
520    9_
$a BACKGROUND: Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy of daclizumab in patients with relapsing-remitting multiple sclerosis (RRMS). We report the long-term safety and efficacy of daclizumab 150 mg subcutaneous every 4 weeks in patients with RRMS in the SELECTED open-label extension study. METHODS: An interim intent-to-treat analysis of all enrolled patients was performed in January 2014 for this ongoing study. RESULTS: The SELECTED study enrolled 90% of patients who completed SELECTION. In the safety and efficacy analysis (N = 410), median treatment time in SELECTED was 25 months (range, <1-45). Adverse events (AEs) were reported in 76% of patients, serious AEs (SAEs) excluding MS relapse in 16%, and treatment discontinuation due to AEs including multiple sclerosis (MS) relapse in 12%. AEs were primarily of mild to moderate severity, and common AEs (≥10%), excluding MS relapse, were nasopharyngitis (12%) and upper respiratory tract infection (12%). Most commonly reported SAEs (in ≥3 patients), excluding MS relapses, were increased serum hepatic enzymes, pneumonia, ulcerative colitis, and urinary tract infection (<1% each). Incidences of AE groups of interest include cutaneous events (28%), cutaneous SAEs (2%), gastrointestinal SAEs (2%), hepatic SAEs, (1%) and malignancies (1%). The incidence of AEs, SAEs, and treatment-related study discontinuations did not increase over time and no deaths were reported. The adjusted annualized relapse rate (95% confidence interval (CI)) analyzed at 6-month intervals was 0.15 (0.10-0.22) for weeks 97-120 and 0.15 (0.10-0.21) for weeks 121-144. In year 3, the adjusted mean (95% CI) number of new/newly enlarging T2 hyperintense lesions was 1.26 (0.93-1.72) and the mean (median) annualized change in brain volume was -0.32% (-0.34%). CONCLUSIONS: The AE incidence did not increase with extension of therapy into year 3 in SELECTED; the safety profile was similar to that previously observed. The clinical efficacy of daclizumab was sustained over the 3 years comprising the SELECT TRILOGY, although potential selection bias cannot be excluded. TRIAL REGISTRATION: Clinicaltrials.gov NCT01051349; first registered January 15, 2010.
650    _2
$a dospělí $7 D000328
650    _2
$a alanintransaminasa $x účinky léků $7 D000410
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D061067
650    _2
$a aspartátaminotransferasy $x účinky léků $7 D001219
650    _2
$a mozek $x účinky léků $7 D001921
650    _2
$a kohortové studie $7 D015331
650    _2
$a ulcerózní kolitida $x chemicky indukované $7 D003093
650    _2
$a léková dermatitida $x etiologie $7 D003875
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobulin G $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D007074
650    _2
$a imunosupresiva $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D007166
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a analýza podle původního léčebného záměru $7 D057194
650    _2
$a receptor interleukinu-2 - alfa-podjednotka $x aplikace a dávkování $x terapeutické užití $7 D053645
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
650    _2
$a nazofaryngitida $x chemicky indukované $7 D009304
650    _2
$a pneumonie $x chemicky indukované $7 D011014
650    _2
$a recidiva $7 D012008
650    _2
$a infekce dýchací soustavy $x chemicky indukované $7 D012141
650    _2
$a bezpečnost $7 D012449
650    _2
$a výsledek terapie $7 D016896
650    _2
$a infekce močového ústrojí $x chemicky indukované $7 D014552
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Radue, Ernst-Wilhelm $u Medical Image Analysis Center, University Hospital Basel, Basel, Switzerland.
700    1_
$a Giovannoni, Gavin $u Queen Mary University of London, Blizard Institute, London School of Medicine and Dentistry, London, UK.
700    1_
$a Selmaj, Krzysztof $u Medical University of Lodz, Lodz, Poland.
700    1_
$a Havrdova, Eva $u First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Stefoski, Dusan $u Rush University Medical Center, Chicago, IL, USA.
700    1_
$a Sprenger, Till $u Medical Image Analysis Center, University Hospital Basel, Basel, Switzerland. DKD Helios Klinik Wiesbaden, Wiesbaden, Germany.
700    1_
$a Montalban, Xavier $u Hospital Vall d'Hebron University, Barcelona, Spain.
700    1_
$a Cohan, Stanley $u Providence Multiple Sclerosis Center, Portland, OR, USA.
700    1_
$a Umans, Kimberly $u Biogen, Cambridge, MA, USA.
700    1_
$a Greenberg, Steven J $u AbbVie Biotherapeutics Inc., Redwood, CA, USA.
700    1_
$a Ozen, Gulden $u Biogen, Cambridge, MA, USA.
700    1_
$a Elkins, Jacob $u Biogen, Cambridge, MA, USA.
773    0_
$w MED00008195 $t BMC neurology $x 1471-2377 $g Roč. 16, č. - (2016), s. 117
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27461166 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170112123624 $b ABA008
999    __
$a ok $b bmc $g 1179379 $s 960806
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 16 $c - $d 117 $e 20160726 $i 1471-2377 $m BMC neurology $n BMC Neurol $x MED00008195
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace